The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of ...

Onc Nurse On Call is the new podcast by Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, AOCN, and ...

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or ...

The combination of carfilzomib (Kyprolis) plus lenalidomide (Revlimid) and dexamethasone (KRd) improved progression-free ...

From clinical trials, to psychosocial needs, to care transitioning, adolescent and young adult patients with cancer face ...

Blinatumomab/ponatinib increased efficacy and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.

After a radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer, patients often face decisions about ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.